$173 Million Launch for Watertown’s Marrow Therapeutics Targets Sickle Cell Disease
Watertown’s Marrow Therapeutics launched Tuesday, Nov. 17, with $173 million for a bone marrow drug for sickle cell and beta thalassemia. What we know.
World News, Politics and War, Reported from Boston
Watertown’s Marrow Therapeutics launched Tuesday, Nov. 17, with $173 million for a bone marrow drug for sickle cell and beta thalassemia. What we know.